Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.
Our goal is to be a leading specialty company, recognized and trusted by patients and providers for our commitment to urology.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients with urological conditions that are overlooked, misunderstood or not well managed.
Careers at Urovant Sciences offer exceptional possibilities.
When you join Urovant Sciences, you become part of our world-class team and dynamic culture where you have the opportunity to develop and grow, personally and professionally.
Careers CTA Image
In The News

April 15, 2021
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
April 12, 2021
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
February 12, 2021
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results